Tools / Drug approvals and letters / Drugs Topiramate Treats partial-onset or primary generalized tonic-clonic seizures. Sold as Topamax, Topamax Sprinkle, Trokendi Xr, Qudexy Xr, Eprontia. Every FDA application for this active ingredient: 5 branded and 54 generic.
As of Nov 15, 2026, FDA lists 59 applications for Topiramate (sold as Topamax, Topamax Sprinkle, Trokendi Xr and others), first approved Dec 24, 1996, with 26 new uses approved and 0 published complete response letters.
First approved : Dec 24, 1996 Applications : 59 New uses approved : 26 Complete response letters : 0 Medicare spending, 2025 : $130M Safety program : REMS
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Topiramate Part D $45.1M +12% 704,319 Topamax Part D $38.2M -8% 2,824 Topiramate ER Part D $19.6M -31% 4,555 Trokendi XR Part D $15.2M -15% 1,123 Topiramate ER Sprinkle Part D $11.0M New 3,057 Eprontia Part D $953K +6% 242 Qudexy XR Part D $289K -76% 65
What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change TOPIRAMATE 100 MG TABLET: $0.059 per unit Generic · -4% in a year TOPIRAMATE 15 MG SPRINKLE CAP: $0.231 per unit Generic · -27% in a year TOPIRAMATE 200 MG TABLET: $0.109 per unit Generic · +7% in a year TOPIRAMATE 25 MG SPRINKLE CAP: $0.245 per unit Generic · -34% in a year TOPIRAMATE 25 MG TABLET: $0.027 per unit Generic · +3% in a year TOPIRAMATE 25 MG/ML SOLUTION: $1.59 per ML Generic · new this year TOPIRAMATE 50 MG SPRINKLE CAP: $4.29 per unit Generic · new this year TOPIRAMATE 50 MG TABLET: $0.040 per unit Generic · +2% in a year TOPIRAMATE ER 100 MG CAPSULE: $9.10 per unit Generic · -30% in a year TOPIRAMATE ER 100 MG SPRINK CAP: $5.78 per unit Generic · -32% in a year TOPIRAMATE ER 150 MG SPRINK CAP: $7.03 per unit Generic · -40% in a year TOPIRAMATE ER 200 MG CAPSULE: $17.41 per unit Generic · -32% in a year FDA Drug Safety Communications One communication since 2020 that name this drug; see all communications Topina Fine, new approval A drug with a new additional pediatric dosage in an additional dosage form. · Kyowa Hakko Kirin Co., Ltd. · Jan 17, 2014 Topina Drugs with a new additional pediatric dosage. · Kyowa Hakko Kirin Co., Ltd. · Nov 22, 2013
Safety Programs (REMS) FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed Clinical Trials 31 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s Obesity & Overweight, Cardiometabolic Health Indicators · Jing Luo Phase 4 Not yet recruiting Sep 21, 2026 Discontinuing Psychotropic Medication Before Psychotherapy for PTSD Post-traumatic Stress Disorder (PTSD) · Academic Centre for Dentistry in Amsterdam — Not yet recruiting Sep 3, 2026 Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission · St. Jude Children's Research Hospital Phase 2 Not yet recruiting Aug 27, 2026 Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy Obesity & Overweight · Phenomix Sciences Not applicable Not yet recruiting Jul 27, 2026 Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary Management Idiopathic Intracranial Hypertension · Sohag University Not applicable Active, not recruiting Jul 16, 2026 Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Migraine Associated Vertigo, Tinnitus · Stanford University Phase 4 Not yet recruiting Jun 17, 2026 Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation Persistent Spinal Pain Syndrome Type 2 (PSPS-T2), Lower Spine, Spinal Cord Sensitivity to Neurostimulation · Brai²n — Recruiting Feb 17, 2026 Combining Latency Reversing Agents to Address the HIV Reservoir HIV (Human Immunodeficiency Virus), HIV -1 Infection · Erasmus Medical Center Phase 1 / Phase 2 Not yet recruiting Feb 3, 2026
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Dec 24, 1996 Topamax NDA 20505 · New molecular entity Janssen Pharms52 Marketed Oct 26, 1998 Topamax, Topamax Sprinkle NDA 20844 · New dosage form Janssen Pharms48 Marketed Dec 17, 2003 Topiramate ANDA 76448 Barr0 Discontinued Mar 27, 2009 Topiramate ANDA 76327 Sun Pharm Inds Ltd13 Discontinued Mar 27, 2009 Topiramate ANDA 76343 Cipla Ltd15 Marketed Mar 27, 2009 Topiramate ANDA 76311 Accord Hlthcare3 Marketed Mar 27, 2009 Topiramate ANDA 77643 Watson Labs1 Discontinued Mar 27, 2009 Topiramate ANDA 78235 Zydus Pharms USA Inc23 Marketed Mar 27, 2009 Topiramate ANDA 78462 Aurobindo Pharma25 Marketed Mar 27, 2009 Topiramate ANDA 79162 Invagen Pharms12 Marketed Mar 27, 2009 Topiramate ANDA 90162 Unichem Labs Ltd16 Marketed Mar 27, 2009 Topiramate ANDA 76314 Natco12 Discontinued Mar 27, 2009 Topiramate ANDA 77733 Pharmaco4 Discontinued Mar 27, 2009 Topiramate ANDA 79153 Torrent Pharms11 Discontinued Mar 27, 2009 Topiramate ANDA 90278 Sun Pharm17 Discontinued Mar 27, 2009 Topiramate ANDA 76317 Teva9 Discontinued Mar 27, 2009 Topiramate ANDA 77627 Glenmark Pharms Ltd15 Marketed Mar 30, 2009 Topiramate ANDA 77905 Pliva Hrvatska Doo0 Discontinued Apr 15, 2009 Topiramate ANDA 77868 Watson Labs5 Discontinued Apr 17, 2009 Topiramate ANDA 76575 Teva19 Discontinued Oct 14, 2009 Topiramate ANDA 78418 Strides Pharma8 Marketed Oct 14, 2009 Topiramate ANDA 78877 Zydus Pharms USA Inc19 Marketed Oct 14, 2009 Topiramate ANDA 79206 Chartwell Rx2 Discontinued Jan 7, 2010 Topiramate ANDA 78499 Aiping Pharm Inc6 Marketed Sep 1, 2010 Topiramate ANDA 90353 Pharmazone1 Discontinued Feb 27, 2013 Topiramate ANDA 78637 Actavis Totowa0 Discontinued Aug 16, 2013 Trokendi Xr NDA 201635 · New dosage form Supernus Pharms20 Marketed Sep 11, 2013 Topiramate ANDA 78410 Chartwell0 Discontinued Nov 25, 2013 Topiramate ANDA 91185 Hikma Pharms0 Discontinued Mar 11, 2014 Qudexy Xr NDA 205122 · New dosage form Upsher Smith Labs12 Marketed Nov 24, 2017 Topiramate ANDA 207382 Zydus5 Marketed Feb 1, 2021 Topiramate ANDA 210278 Glenmark Pharms Ltd4 Marketed Aug 26, 2021 Topiramate ANDA 215414 Ascent Pharms Inc2 Marketed Nov 5, 2021 Eprontia NDA 214679 · New dosage form Azurity4 Marketed Nov 28, 2022 Topiramate ANDA 208949 Zydus2 Marketed Feb 9, 2023 Topiramate ANDA 216167 Zydus Pharms0 Discontinued Mar 10, 2023 Topiramate ANDA 206210 Actavis Labs Fl3 Marketed May 4, 2023 Topiramate ANDA 205976 Ph Health0 Marketed Jun 20, 2023 Topiramate ANDA 217248 Alkem Labs Ltd3 Marketed Aug 15, 2023 Topiramate ANDA 215663 Ajanta Pharma Ltd3 Marketed Sep 27, 2023 Topiramate ANDA 215449 Aurobindo Pharma Ltd1 Marketed Nov 17, 2023 Topiramate ANDA 217231 Dr Reddys0 Marketed Dec 5, 2023 Topiramate ANDA 217694 Twi Pharms0 Marketed Jun 13, 2024 Topiramate ANDA 218482 Alkem Labs Ltd1 Marketed Jul 11, 2024 Topiramate ANDA 215561 Lupin0 Marketed Jul 16, 2024 Topiramate ANDA 217869 Glenmark Pharms Ltd1 Marketed Oct 10, 2024 Topiramate ANDA 218642 Pharmazone0 Marketed Oct 31, 2024 Topiramate ANDA 217795 Alkem Labs Ltd1 Marketed Nov 5, 2024 Topiramate ANDA 215638 Xiamen LP Pharm Co0 Marketed Dec 3, 2024 Topiramate ANDA 218695 Amta1 Marketed May 27, 2025 Topiramate ANDA 216683 Rubicon Research0 Marketed Sep 2, 2025 Topiramate ANDA 219564 Ajanta Pharma Ltd0 Marketed Jan 12, 2026 Topiramate ANDA 217443 Ascent Pharms Inc0 Marketed May 26, 2026 Topiramate ANDA 220041 Riconpharma LLC0 Discontinued Jul 22, 2026 Topiramate ANDA 220943 Biocon Pharma0 Marketed Sep 4, 2026 Topiramate ANDA 219183 Micro Labs0 Marketed — Topiramate ANDA 76306 Roxane0 Discontinued — Topiramate ANDA 76315 Barr0 Discontinued — Topiramate ANDA 219207 Zhejiang Poly Pharm Co Ltd0 Discontinued
Show all 59Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA